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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is becoming the second leading 
cause of cancer-related death in the Western world. The mortality is very high, 
which emphasizes the need to identify biomarkers for early detection. As glutamine 
metabolism alteration is a feature of PDAC, its in vivo evaluation may provide a useful 
tool for biomarker identification. Our aim was to identify a handy method to evaluate 
blood glutamine consumption in mouse models of PDAC. We quantified the in vitro 
glutamine uptake by Mass Spectrometry (MS) in tumor cell supernatants and showed 
that it was higher in PDAC compared to non-PDAC tumor and pancreatic control 
human cells. The increased glutamine uptake was paralleled by higher activity of 
most glutamine pathway-related enzymes supporting nucleotide and ATP production. 
Free glutamine blood levels were evaluated in orthotopic and spontaneous mouse 
models of PDAC and other pancreatic-related disorders by High-Performance Liquid 
Chromatography (HPLC) and/or MS. Notably we observed a reduction of blood 
glutamine as much as the tumor progressed from pancreatic intraepithelial lesions 
to invasive PDAC, but was not related to chronic pancreatitis-associated inflammation 
or diabetes. In parallel the increased levels of branched-chain amino acids (BCAA) 
were observed. By contrast blood glutamine levels were stable in non-tumor bearing 
mice. These findings demonstrated that glutamine uptake is measurable both in 
vitro and in vivo. The higher in vitro avidity of PDAC cells corresponded to a lower 
blood glutamine level as soon as the tumor mass grew. The reduction in circulating 
glutamine represents a novel tool exploitable to implement other diagnostic or 
prognostic PDAC biomarkers.
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INTRODUCTION
Pancreatic Ductal Adenocarcinoma (PDAC) is 
the fourth leading cause of cancer mortality in Western 
countries, with a very low improvement of the survival rate 
over the last four decades [1]. To date, the only treatment 
with curative intent is surgery, but as a silent killer, PDAC 
symptoms are so well-hidden that around 85% of people 
are diagnosed at an advanced stage of the disease leading 
to poor prognosis and incidence equaling mortality [2]. For 
this reason, identification of new circulating diagnostic 
markers as well as targets for the design of novel therapies 
for PDAC is crucially important [1, 3, 4]. The serum marker 
- Carbohydrate Antigen 19.9 (CA19-9) - is widely accepted 
as a prognostic PDAC marker, but due to its poor sensitivity 
and specificity is unsuitable for early detection of PDAC [4, 
5]. In the last 20 years, many biomarkers have been studied 
for potential use in PDAC diagnosis, but none of them has 
shown clinical benefits [5].
Oncogenes and tumor suppressors as K-Ras and 
TP53 are highly integrated in metabolic processes [6, 7]. 
In some tumors, besides glucose metabolism, glutamine is 
a key substrate required for anabolic growth of mammalian 
cells [8, 9]. In K-Ras mutated tumor cells, glutamine is 
one of the major source of carbon for ATP production, 
nucleotide and protein biosynthesis and regulator of redox 
balance [10, 11]. Due to the importance of glutamine for 
cell survival and proliferation, many newly-developed 
diagnostic imaging techniques have focused on glutamine 
instead of glucose [12, 13, 14].
In this study, we aimed at the identification of a handy 
tool for the evaluation of circulating glutamine. Firstly, we 
assessed glutamine consumption in vitro in PDAC and non-
PDAC tumor cells and control human pancreatic cells. The 
former showed a higher glutamine uptake that we correlated 
with an increased activity and expression of glutamine 
pathway-related enzymes. Finally, we measured the levels 
of circulating free glutamine, by HPLC [15, 16] or MS [17], 
in both an orthotopic and a genetically engineered mouse 
(GEM) model of PDAC [18]. In both models, a decrease 
of glutamine blood levels was detected and this was 
associated with the growing tumor mass and the progression 
from pancreatic intraepithelial lesions (PanIN) to invasive 
PDAC. These findings indicating that the decrease of 
circulating glutamine is a feature specifically associated to 
PDAC progression, may efficiently implement other PDAC 
diagnostic biomarkers.
RESULTS
PDAC cells display an increased in vitro 
glutamine uptake
We have measured the uptake of glutamine in 
murine [18] and human PDAC and non-PDAC cell lines, 
derived from human breast adenocarcinoma and a human 
lung adenocarcinoma, and a pancreatic ductal epithelial 
cell line (HPDE) used as control. Such tumor cells can 
have either a single K-Ras or TP53 mutation, or combined 
K-Ras and TP53 mutations (Supplementary Table 1).
Cells were incubated with medium supplemented 
with glutamine and its uptake was kinetically followed at 
several time points on the basis of residual glutamine in 
the medium. The normalized percentage uptake %Un is 
plotted against incubation time in Figure 1. HPDE cells 
showed a very low uptake of glutamine at 15 min that 
lasted until 120 min (Supplementary Table 1 and Figure 
1A), with a very little delta (Δ120-0 %Un) of uptake between 
0 and 120 min (Supplementary Table 1). Non-PDAC 
cancer cells NCI-H441 and MDA-MB-231, both featuring 
the combined K-Ras and TP53 mutations, also showed a 
low rate of uptake, being similar to that of HPDE cells 
(Supplementary Table 1 and Figure 1B). The same trend 
was observed in other breast cancer cells, with exception 
of DU4475 cells, derived from a Triple Negative Breast 
Cancer (TNBC) (Supplementary Table 1 and Figure 1B). 
By contrast, in all human and murine PDAC cells mutated 
in K-Ras only or in the combination with TP53 there was a 
significant and lasting glutamine uptake from 0 min to 120 
min, (Supplementary Table 1 and Figure 1C-1D). These 
findings are in agreement with our and others studies 
demonstrating that oncogenic K-Ras plays a critical role 
in affecting glutamine metabolism specifically in PDAC 
[11, 19]. To confirm K-Ras role in glutamine uptake we 
assessed the glutamine uptake in HPDE cells expressing 
the mutated K-Ras oncogene. A significantly higher %Un 
compared to HPDE cells expressing the control vector 
was observed (Figure 1E). The minimal role of TP53 
in affecting glutamine uptake was demonstrated by the 
evidence that BxPC3 cells showed a similar uptake rate of 
unmutated HPDE cells (Figure 1F).
PDAC cells rely on glutamine to support 
nucleotide biosynthesis and ATP production
The increased glutamine uptake observed in 
PDAC cells led us to analyze the activity of the enzymes 
involved in glutaminolysis, assuming that PDAC cells 
subsequently catabolize all the internalized glutamine. 
Glutamine catabolism begins with glutaminase (GLS), an 
amidohydrolase that catalyzes the conversion of glutamine 
to glutamate (Figure 2) [20, 21]. We observed that the 
overall enzymatic activity of GLS was significantly reduced 
in all PDAC and non-PDAC cell lines tested, compared to 
HPDE cells (Figure 3A). These results suggest that GLS is 
not the key glutamate-producing enzyme in PDAC cells.
Downstream of glutaminase, glutamine catabolism 
can proceed by means of the mitochondrial matrix enzyme 
glutamate dehydrogenase (GDH), which generates 
α-ketoglutarate, or via aspartate transaminase (AST/GOT), 
which exists in cytoplasmic and mitochondrial forms, 
GOT1 and GOT2, respectively (Figure 2) [4, 11]. AST 
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catalyzes the transfer of the amino group from glutamate 
to α-ketoglutarate, to form aspartate from TCA cycle-
derived oxaloacetate. Both these metabolic pathways were 
shown to be increased in almost all of the studied PDAC 
cell lines compared to control human and non-PDAC cell 
lines (Figure 3B–3C). The enzyme mRNA expression 
was evaluated by qRT-PCR analysis, confirming the 
decrease of GLS expression in tumor cell lines compared 
to HPDE (Supplementary Figure 1A), and the increase 
of mRNA levels of both GDH1 and GDH2 in PDAC cell 
lines compared to non-PDAC and control human cells 
(Supplementary Figure 1B-1C).
The gain of glutamate-catabolic enzymes and 
the simultaneous reduction of GLS activity led us to 
investigate other metabolic pathways involved in the 
production of glutamate. As glutamine serves as an 
essential nitrogen donor in purine and pyrimidine synthesis 
[7], the activity of glutamine amidophosphoribosyl 
transferase (GPAT) and carbamoyl phosphate synthetase 
II (CPSII), involved in the first steps of purine and 
pyrimidine biosynthesis respectively, were higher in all 
PDAC cell lines compared to non-PDAC and control 
human cells (Figure 3D–3E). At the same extent also AST, 
GPAT and CPSII mRNA expression levels were higher 
Figure 1: PDAC cells exhibit an increased in vitro glutamine uptake. (A-F) Glutamine uptake was evaluated as the amount of 
2-15N-Gln lasting in culture media from 0 to 120 min. The uptake is expressed as % of glutamine in culture medium. Results are represented 
as mean±SEM of triplicates of two independent experiments. SEM less than 10% of the value is not visible in the graph. Curves were 
compared by two-way ANOVA, *** P <.001.
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in PDAC cell lines compared to non-PDAC and control 
human cells (Supplementary Figure 1D-1F). These results 
suggest that PDAC cell lines have different glutamine 
metabolism compared to the non-PDAC cell lines, despite 
the presence of mutated K-Ras.
Furthermore, the increased expression of GDH1 
and CPSII was also observed by immunohistochemistry 
(Supplementary Figure 2), confirming a higher presence of 
both enzymes in the pancreas of both orthotopic and GEM 
models of PDAC in comparison to WT mice.
In addition, the TCA cycle rate was significantly 
increased in all PDAC and non-PDAC cell lines compared 
to HPDE control cells (Figure 4A). Consequently, the 
global electron flux and the activity of each mitochondrial 
complex were increased (Figure 4B–4F). This up-
regulation that led to a strong increase in ATP synthesis 
supporting all the above-mentioned biosynthetic reactions 
is not so unexpected in all tumor cells (Figure 4G).
PDAC cells utilize the ASCT2 antiport to 
regulate glutamine uptake
As we reported an increased glutamine uptake 
and metabolism in PDAC cells, we wondered which 
transmembrane protein was responsible for its internalization. 
We focused on two transporters already described to be 
correlated to PDAC [22, 23], namely AlaSerCys Transporter 
2 (ASCT2) (Figure 5A) [24] and the Light subunits of 
Amino acid Transporters 1 (LAT1) (Figure 5A) [25]. The 
former is the major glutamine importer whereas the latter is 
a glutamine exporter.
An overall up-regulation of ASCT2 mRNA levels 
and a simultaneous down-regulation of LAT1 expression 
occurred in most of PDAC cell lines compared to HPDE 
cells (Figure 5B–5C).
Circulating glutamine decrease correlates with 
PDAC progression rather than inflammation or 
diabetes
To verify that the increased glutamine uptake and 
metabolism in cultured PDAC cell lines was not an artifact 
due to the in vitro culture conditions [26], we stepped 
into in vivo models. We speculated that the endogenous 
circulating glutamine levels were decreased in vivo during 
PDAC growth as a result of its increased uptake and 
consumption by tumor cells. To this end, K8484 cells were 
orthotopically injected into the pancreas of C57BL/6 mice, 
and endogenous circulating glutamine levels were assessed 
in parallel with the tumor mass. Hundred thousand of 
Figure 2: Glutamine metabolism in PDAC cells. Cartoon representing metabolic pathways in proliferating cells. Glucose 
(Glu) and glutamine (Gln) are metabolized into critical intermediates that are necessary for energy balance and cellular growth, 
such as nucleotides, amino acids and lipids. Key enzymes in glutaminolysis are discussed in the text (shown in red). Α-KG, 
α-ketoglutarate; OAA, oxaloacetate; Ac-CoA, acetyl coenzymeA; Asp, aspartate; CPSII, carbamoyl phosphate synthetase 
II; GSH, glutathione; GSSG, oxidized glutathione; GLS, glutaminase; GPAT, glutamine amido phosphoribosyl transferase; 
ME1, malic enzyme 1; AST, glutamic-oxaloacetic transaminase; GDH, glutamate dehydrogenase; TCA cycle, tricarboxylic 
acid cycle.
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K8484 mixed with matrigel are able to give a mass of 
around 1 gr of weight by 28 days when injected into the 
pancreas of syngeneic mice [27]. Endogenous circulating 
glutamine levels were assessed at 0, 15 and 30 days after 
injection by HPLC [15, 16], and MS [17]. When tumor 
grew (Supplementary Figure 3A), circulating glutamine 
levels significantly decreased (Figure 6A–Supplementary 
Figure 3B). Such decrease was consistently maintained 
until the end of the experiment (Figure 6A–Supplementary 
Figure 3B).
To further validate the correlation between PDAC 
onset and progression and the reduction in circulating 
glutamine, we measured it in both female and male 
GEM mice carrying single-mutated KrasG12D (KC), 
ranging from 1.5 to 9 months of age. As shown in Figure 
6B-Supplementary Figure 3C, in 3-month-old mice, a 
significant reduction in the blood glutamine levels was 
observed. This reduction was much more pronounced in 
6-month-old mice and still observed in 9–month-old mice. 
Remarkably, the reduction was observed as early as PanIN 
Figure 3: PDAC cells rely on glutamine to support nucleotide biosynthesis. (A-E) Analysis of the enzymatic activity of: GLS 
(A), GDH (B), AST (C), GPAT (D) and CPSII (E) in control human pancreatic cells HPDE (white bar), human pancreatic tumor cells PT45, 
MiaPaCa2, PANC1, T3M4, Hs766T, CFPAC1, Colo-357-L3.6pl (light grey bars), murine pancreatic tumor cells K8484, DT6606, DT4313 
(black bars) and non-PDAC cells NCI-H441 and MDA-MB-231 (dark grey bars). Activity is expressed as nmol of NADH consumed in 
1 min per mg of protein for GLS and GDH; nmol of glutamate consumed in 1 min in 1 ml per mg of protein for AST; pmol of glutamate 
consumed in 1 hour per mg of protein for GPAT and pmol of carbamoyl aspartate in 1 min per mg of protein for CPSII. Results are 
represented as mean±SEM of triplicates of two independent experiments. * P <.05; ** P <.01; *** P <.001 values different from those obtained 
with the HPDE cell line.
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Figure 4: Oxidative phosphorylation is increased in PDAC cells. (A) The TCA cycle rate was evaluated by measuring CO2 
emission after radiolabeling cells with [1-14C] acetylcoenzyme A in human HPDE cells (white bars) and human PDAC cell lines (light grey 
bars), murine (black bars) PDAC cell lines and non-PDAC cells line (dark grey bars) expressed as pmol of CO2 consumed in 1 min per 
mg of protein. (B-F) Analysis of the global electron flux (B)and of the mitochondrial respiratory chain complexes I-IV activity (C-F) that 
is expressed as nmol of NAD+ produced in 1 min per mg of mitochondrial protein for complex I, nmol of reduced Cytc in 1 min per mg 
of mitochondrial protein for the global electron flux and for complexes II-III and nmol of oxidized Cytc in 1 min per mg of mitochondrial 
protein for complex IV. (G) Analysis of ATP production, expressed as nmol of ATP consumed per mg of protein. All graphs represent 
mean±SEM of triplicates. * P <.05; ** P <.01; *** P <.001 significance values, compared to those obtained with the HPDE cell line.
Oncotarget95367www.impactjournals.com/oncotarget
were detectable and independent from the mouse gender. To 
rule out aging as a possible factor affecting free glutamine 
levels in blood [28, 29], we measured it in healthy WT mice 
and there was no glutamine decrease at all as shown in 
Supplementary Figure 3D. This confirms that the decrease 
of circulating glutamine is a feature-associated to PDAC 
onset and progression. As it has been noticed that an higher 
plasmatic level of BCAA correlated with an higher risk 
of PDAC development [30, 31], we quantified BCAAs in 
KC mice. Valine (Figure 6C), Isoleucine (Figure 6D) and 
Leucine (Figure 6E) were significantly increased when 
evaluated both in single and all together (Figure 6F).
Orthotopic procedures may cause inflammation 
and in humans, onset of PDAC can be associated with 
long-standing chronic pancreatitis [32]. To rule out the 
involvement of inflammation in the modulation of the 
blood glutamine level, we compared endogenous glutamine 
variation in C57BL/6 mice before and after caerulein–
induced acute and chronic pancreatitis. As previously 
reported [33, 34], after the induction of acute pancreatitis 
there were no differences in pancreas weight (Figure 7A), 
although the histological analyses indicated tissue damage 
in the caerulein-treated mice but not in the PBS-treated 
group (Figure 7C). Repeated injections of caerulein (4-
week treatment), however, induced an increase in pancreas 
weight (Figure 7A), and marked morphological changes 
with an alteration in acinar units due to increased space 
between neighboring cells, swollen cytoplasm and more 
centrally-located nuclei (Figure 7C). Although some 
variability among mice, no significant variations in the 
amount of circulating glutamine were observed (Figure 7B). 
Therefore, the reduction in circulating glutamine was 
dependent on PDAC transformation rather than its 
associated inflammation. Since there is a strong correlation 
between type 2 diabetes (T2D) and PDAC [35], to verify 
that circulating glutamine levels were not affected by 
diabetes onset, we set up a T2D mouse model [36, 37]. The 
model has shown to be accompanied by insulin resistance, 
Figure 5: PDAC cells utilize the ASCT2 antiport to regulate glutamine uptake. (A) Schematic representation of ASCT2 and 
LAT1 transmembrane proteins (B-C) mRNA expression analysis of ASCT2 (B) and LAT1 (C) in HPDE (white bar), human (light grey 
bars) and murine (black bars) PDAC cell lines and non-PDAC cells (dark grey bars). Results are represented as mean of 2-DCt±SEM of 
triplicates of two independent experiments * P <.05; ** P <.01; *** P <.001 significance values, compared to those obtained with the HPDE 
cell line.
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as determined by intravenous glucose tolerance tests 
(IVGTT) 6 weeks after a High-Fat Diet (HFD) regimen 
(Figure 7D), but interestingly the circulating glutamine 
levels after 3 and 6 weeks of HFD resulted significantly 
increased (Figure 7E).
DISCUSSION
The essential requirement of proliferating cells for 
glutamine was described by Eagle, who observed that 
glutamine consumption rate of many tumor cells exceeded 
Figure 6: Glutamine decrease and BCAAs increase are linked to PDAC progression in KC mice. (A) C57BL/6 mice were 
injected orthotopically into the pancreas with K8484 cells. Total blood glutamine concentration was evaluated using an HPLC instrument at 
the indicated time points. Results are represented for each mouse (10 mice/each time point) and mean±SEM are indicated. (B-F) Analysis of 
total glutamine (B), valine (C), isoleucine (D), leucine (E) and total branched-chain amino acids concentration (F) in KC mice (3-10 mice/
group) at the indicated time points compared to control group (mice <2 months old). * P <.05; ** P <.01; *** P <.001 values at days 15 and 30 
significantly different from those measured at day 0, and KC and WT mice older than 2 months compared to mice less than 2 months old.
Oncotarget95369www.impactjournals.com/oncotarget
the consumption of any other amino acid by 10-fold [38, 
19]. Among the other energy fuels, glutamine is the most 
abundant amino acid in the blood and the main donor of 
nitrogen. PDAC cells are termed as “glutamine-addicted” 
as their glutamine demands are known to exceed the 
physiological need of this metabolite [4, 39]. In the current 
study, we exploited a non-invasive tool for assessing the 
total glutamine uptake in PDAC mouse models, exploring 
the hypothesis that the increased glutaminolysis was 
maintained in vivo, thus revealing reduction of circulating 
Figure 7: The decrease in circulating glutamine does not correlates with inflammation. (A-C) Acute (AC) and Chronic 
Pancreatitis (CP) were induced in C57BL/6 mice through several injections of caerulein. A. Pancreases were collected and weighed from 
PBS-treated control and AC- and CP-affected mice. B. Graph represents percentage of blood glutamine compared to control group after 
induction of pancreatitis (5-8 mice/time point). Mean±SEM are indicated. E. H&E staining of pancreas sections of control mice, and acute 
and chronic pancreatitis-affected mice. (D) Plasma glucose concentrations during the intravenous glucose tolerance test (1 g/kg) in mice 
fed with Normal Diet or with High-Fat Diet for six weeks. Blood was sampled at 0, 1, 10, 30 and 50 minutes and glucose concentration is 
expressed as mg/dl. (E) Graph represents percentage of blood glutamine of mice before HFD feeding (time 0) versus 3 and 6 weeks of HFD 
feeding (5 mice/time point). Mean±SEM are indicated. * P <.05; ** P <.01; *** P <.001 values showing a significant difference of AP and CP 
compared to the control group for the pancreatitis model and HFD-fed mice compared to time 0.
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glutamine levels. A recent published work proposed the 
use of circulating metabolites, in particular BCAA, as an 
indication of future PDAC diagnosis [30]. Mayers et al., 
indeed, observed that an early event of PDAC progression 
related to the cachexia, is their increased plasma levels 
[31]. Another group proposed as PDAC diagnostic and 
prognostic tool the evaluation of proteins present in tumor 
cell-derived exosomes, one for all glypican1 [40, 41]. In 
our study we exploited two minimally-invasive methods to 
assess the levels of circulating glutamine: a semiquantitative 
MS [17] and a quantitative HPLC method [15, 16]. Of note, 
the latter is already used in clinical contexts to measure 
amino acid profiles for diagnosis and monitoring of 
metabolic diseases [15, 16].
As proof-of-concept, we evaluated the in vitro 
glutamine uptake rate of a large set of PDAC cell lines by 
using the 2-15N-Gln isotopomer. We observed a significant 
increase in glutamine uptake by all PDAC cells assessed. 
Many oncogenes or tumor suppressor genes are involved 
in modulating the metabolic state of cells: c-Myc [42] and 
mTORC1 [43] have been linked to enhanced glutamine 
anaplerosis for fueling growth and proliferation by activating 
GDH. Glutamine metabolism is also regulated by hypoxia 
through HIF-1 activation [44]. In mutated K-Ras PDAC, 
glutamine supports cell growth [11] by a non-canonical 
pathway: the conversion of glutamine into oxaloacetate and 
subsequently into malate and pyruvate rather than alpha-
ketoglutarate. On the other hand, TP53 mediates tumor 
suppression through induction of GLS2 expression to fuel 
GSH synthesis in response to reactive oxygen species (ROS) 
[45]. We did not observe any differences in glutamine uptake 
by PDAC cells with mutated K-Ras alone or in combination 
with mutated TP53 (Supplementary Table 1). Moreover, 
even if only one tumor cell line showing the presence of 
mutated TP53 alone was analyzed, this latter seems to be 
no sufficient to elicit a glutamine-dependent phenotype. 
These results highlight that K-Ras mutations drive the 
increase of glutamine uptake by PDAC independently from 
the mutational status of TP53. This observation was also 
demonstrated by the higher uptake of glutamine evaluated 
in human pancreatic duct epithelial cells forced to express 
the mutated K-Ras oncogene compared to the control vector 
expressing cells. In our study, both breast and lung cancer 
cells displayed a very low in vitro glutamine uptake with 
exception of DU4475 cells, which are derived from a TNBC. 
Breast cancer cells are indeed heterogeneous and may be 
also subdivided according to their glutamine addiction 
independently from K-Ras mutation [46], with TNBC 
showing increased glutamine dependency compared to Triple 
Positive Breast Cancer (TPBC) [47]. The large set of PDAC 
cells with similar trend confirms that generally PDAC is 
more “glutamine addicted” than other cancers [46, 48].
The increased in vitro glutamine uptake by PDAC 
cells is to satisfy their glutamine needs. Proteomic analysis 
identified several enzymes involved in glutaminolysis in 
the PDAC cells, and revealed an increased production of 
glutamine-derived nucleotides through GPAT and CPSII 
enzymes [4, 19, 49]. This results in an increased glutamate 
pool that is metabolized by GDH to α-KG [50] and by AST 
pathway to aspartate to regulate K-Ras-dependent redox 
stress [11]. Glutamine catabolism can also proceed via GLS, 
producing glutamate and ammonia [50]. In mammals, the 
two major isoforms are linked to different pathways for 
sustaining cell proliferation and survival: GLS1 expression 
is enhanced by c-Myc [42], it favors cell survival and 
proliferation and promotes the entry of glutamine into the 
TCA cycle [50]. By contrast, GLS2 expression is regulated 
by TP53, it increases cellular antioxidant activities and 
regulates energy metabolism [51]. Here, all the PDAC cells 
analyzed showed an increase in GPAT and CPSII activities, 
mRNA and protein expression to produce nucleotides and 
glutamate, in GDH activity mRNA and protein expression 
to metabolize glutamate and in AST activity to produce 
aspartate to fuel the TCA cycle. By contrast, GLS activity 
and mRNA levels decreased in most of PDAC cells. Our 
results suggest that glutamine catabolism is shifted from 
GLS to GPAT and CPSII, to satisfy nucleotide demand. 
In non-PDAC cells, we observed a marked reduction of 
GLS, GDH, GPAT and CPSII activity, highlighting that 
the glutamine metabolism through GPAT/CPSII and GDH 
is typical of PDAC cells and accounts for the increased 
glutamine uptake.
Rapidly growing cells tend to use the carbon skeleton 
of glutamine as a respiratory substrate [7, 20]. As expected, 
in all the analyzed PDAC cells, we observed an upregulation 
of the mitochondrial oxidative phosphorylation, which led 
to an increase of the ATP pool [50] to support proliferation 
and survival.
Most cells can synthesize glutamine de novo, 
although tumor cells being in rapid growth take up as 
many nutrients as possible to satisfy increased metabolic 
requirements [22]. Therefore, is of advantage to use 
transporters to maximize nutrition incorporation. In 
PDAC cells, glutamine is mainly transported by ASCT2 
and LAT1 [23]. Although it has been reported that high 
expression of ASCT2 and LAT1 may represent a marker 
of poor prognosis in PDAC [24, 25], in all PDAC cells 
assessed, only ASCT2 was up-regulated at the mRNA 
level while LAT1 expression was down regulated. This 
preferential use of ASCT2 could be attributed to the need 
of protein synthesis through glutamine [22]. In addition, 
LAT1 mRNA reduced expression could be due to a 
different post-transcriptional in vitro stabilization or to the 
absence in cultured conditions of tumor stroma that might 
lead to its expression to compensate the nutrient shortage.
To translate the in vitro observation into the clinical 
practice, we exploited an orthotopic and autochthonous 
mouse models of PDAC. Both C57BL/6 mice, injected 
with syngeneic PDAC cells, and GEM mice displayed 
lower levels of circulating glutamine as early as tumors 
appeared and progressed. GEM mice [18] showed a 
reduction in plasmatic glutamine levels, paralleled with 
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the increase in BCAAs levels, from PanIN to invasive 
PDAC compared to their normal littermates of same age, 
indicating that these differences could not be ascribable to 
aging or gender, but solely to PDAC transformation and 
progression. Interestingly Mayers et al. [30] that described 
an increase in BCAAs levels did not report glutamine 
variation in their patients cohort or murine samples. This 
could be due to the short glutamine half-life that requires 
immediate and fast pre-analytical samples treatment.
To rule out any effect due to inflammation 
associated with PDAC progression [32], we induced 
acute and chronic pancreatitis [33] as well as T2D [35, 
52]. Although mice with pancreatitis showed an increased 
pancreas weight and the presence of histological 
alterations, chronic pancreatitis did not affect circulating 
glutamine concentration. As T2D can be a consequence 
or a cause of PDAC progression, we fed C57BL/6 mice 
with 6 weeks of HFD. This models has, accordingly, 
been used in studies on pathophysiology of impaired 
glucose tolerance and T2D: it is characterized by fasting 
hyperglycemia, which contributes in reducing glucose-
mediated insulin secretion and in the efficiency of glucose 
uptake by the insulin sensitive tissues [37, 36]. IVGTT 
was performed at 6 week after introduction of HFD, and 
HFD–fed mice were glucose intolerant and had impaired 
glucose-stimulated insulin secretion compared to normal 
diet-fed mice. Furthermore, blood samples were analyzed 
to test circulating glutamine levels and we found an 
increased amount of glutamine compared to the same mice 
before HFD feeding. It has been proved that L-glutamine 
triggers the secretion of glucagon-like peptide-1 (GLP-1) 
from intestinal cells of mice in response to elevated blood 
glucose levels, mirroring insulin’s release from pancreas 
[53, 54]. Like insulin, GLP-1 lowers blood glucose level, 
therefore an increase of glutamine release in the blood 
of HFD-fed mice may be an attempt to auto-regulate 
glucose levels during T2D onset. Therefore, the reduction 
of circulating glutamine was due to the tumor growth. 
Data on in vitro glutamine uptake we obtained fit in well 
with those observed in vivo. Thus, the concern raised 
on discrepancy between in vitro and in vivo glutamine 
homeostatic regulation with lung cancer cells [26], does 
not apply to our study.
This study unveils a novel biomarker associated 
to PDAC, taking advantage of its increased glutamine 
uptake and catabolism, and an HPLC-based method to 
evaluate circulating glutamine levels with a minimally 
invasive blood collection followed by a fast and cheap pre-
analytical sample treatment. Moreover, as the International 
Cancer of the Pancreas Screening (CAPS) Consortium 
has released consensus guidelines for pancreatic cancer 
screening for the individuals with specific mutational 
features defined “high-risk”, it will be compelling to 
develop a clinical trial to validate our data in a cohort 
of healthy, high-risk subjects, and PDAC patients to fast 
translate this method into the clinic.
MATERIALS AND METHODS
Cell culture
The cell lines used in this study were: CFPAC1, 
BxPC3, MCF7, BT494, DU4475 and MiaPaCa2 (all from 
ECACC), T3M4, PANC1, Hs766T, Colo-357-L3.6pl, PT45 
and HPDE (all kindly provided by Dr. Paola Nisticò, Regina 
Elena National Cancer Institute, Rome, Italy), MDA-
MB-231 (kindly provided by Dr. P. Michieli, University of 
Turin, Turin, Italy), NCI-H441 (kindly provided by Dr. R. 
Chiarle University of Turin, Turin, Italy), HPDE ctrl and 
HPDE K-Ras mut (all kindly provided by Dr. P. Allavena). 
The murine cell line K8484, isolated from a tumor arising 
in LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) 
mouse [18] , DT6606 and DT4313, isolated from a tumor 
arising in LSL-KrasG12D/+;Pdx-1-Cre (KC) mouse, were 
kindly provided by Dr. K. P. Olive (Columbia University, 
New York, NY). Cells were cultured at 37°C in Dulbecco’s 
modified Eagle’s medium (DMEM) (Lonza) supplemented 
with 2 mM L-glutamine (Gibco), 10% fetal bovine serum 
(FBS) (Lonza), and 50 mg/mL Gentamycin (Sigma-
Aldrich) with humidified 5% CO2. All cell lines were tested 
routinely for mycoplasma contamination.
Glutamine uptake in vitro
Cells were plated on poly-L-lysine (Sigma Aldrich) 
for 24 h in complete medium, then were washed twice 
with phosphate-buffered saline (PBS) and incubated at 
37°C with 1 ml of EBSS buffer (1.80 mM CaCl
2;
 5.30 
mM KCl; 0.80 mM MgSO4; 117 mM NaCl; 26 mM 
NaHCO3; 5.60 mM Glucose; pH 7.4) with or without 1 
mM 2-15N-L-glutamine (2-15N-Gln, Cambridge Isotope 
Laboratories). Supernatants were collected at fixed time 
points (0, 15, 30, 60 and 120 min), frozen and cells 
were detached. Protein content was measured using the 
CB-X protein assay kit (Cabbru). Aliquots (450 μl) of 
supernatants were mixed with 50 μl of EBSS buffer 
containing 10 mM N-Acetyl-L-Glutamine (Sigma 
Aldrich) as internal standard immediately prior to 
analysis and subjected to the analytical determination of 
the 2-15N-L-glutamine amount by MS [17]. We obtained 
a curve representing the uptake of 2-15N-L-glutamine 
expressed as percentage of normalized uptake %Un = 
100 (1- Ct/ C0) / d, in which C0 is the concentration of 
2-15N-Gln in the medium at time 0, Ct is the concentration 
of 2-15N-Gln in the medium at the considered time point 
and d is the total protein content (mg).
Mass spectrometry analysis
A Waters instrument with a 515 HPLC pump system 
and a 3100 mass detector was used. The system was 
coupled with a quadrupole mass spectrometer equipped 
with an ESI ion source. The solvent was composed of 
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acetonitrile + 0.1% HCOOH/water + 0.1% HCOOH. The 
flow rate was 1 ml/min and the electrospray ionization 
(ESI) was operated in the positive mode. Other MS 
parameters were as follows: capillary voltage 3kV, cone 
voltage 15V, source temperature 110°C, desolvation gas 
temperature 220°C, desolvation gas flow 500 l/h, cone 
flow 50 l/h. Analysis of the results was performed using 
the MassLynx software (Waters) (the same used for the 
system and data control).
Glutamine catabolism and purine synthesis and 
pyrimidine synthesis
Glutamine catabolism and purine synthesis and 
pyrimidine synthesis were measured as reported in Capello 
et al. [49].
Aspartate aminotransferase (AST) activity
Cells were washed with fresh medium, detached 
with trypsin/EDTA (0.05/0.02% v/v) and then washed 
twice with ice-cold PBS. The AST activity was measured 
using the Aspartate Aminotransferase Activity Assay 
(Sigma Aldrich), using a Synergy HT Multi-Mode 
Microplate Reader (Bio-Tek Instruments, Winooski, VT). 
The protein content of each lysate was quantified using 
the CB-X protein assay kit (Cabbru), and the AST activity 
was expressed as nmol of Glu/min/mL/mg cell proteins.
Quantitative RT-PCR
Total RNA was extracted using the TRI Reagent 
(Sigma Aldrich) and reverse transcription was performed 
with 1 μg of total RNA using iScript cDNA synthesis kit 
according to the manufacturer’s instructions (Bio-Rad). 
Quantitative RT-PCR was performed with SYBR Green 
dye (Life Technologies) on a Thermal iCycler (Bio-Rad). 
PCR reactions were performed in triplicate and the relative 
amount of cDNA was calculated with the comparative 
CT method using β-actin RNA sequences as a control 
for human cell lines, and glyceraldehyde 3-phosphate 
dehydrogenase RNA sequences as a control for murine 
cell lines. We did not perform the reaction on murine 
GDH2 because, in this organism, it is still a pseudogene.
Tricarboxylic acid cycle (TCA) and ATP
TCA cycle and ATP were measured as reported in 
Capello et al. [49].
Mitochondrial respiratory chain
Mithochondrial extracts were prepared as reported 
for ATP quantification [49]. A 50 μL was sonicated 
and used for measuring the protein content. The rate of 
cytochrome c (cyt c) reduction was taken as an index of 
the activity of mitochondria respiration, according to [55] 
with minor modifications. Non-sonicated mitochondrial 
samples (50 μg) were re-suspended in 0.59 mL buffer A (5 
mmol/L KH2PO4, 5 mmol/L MgCl2, 5% w/v bovine serum 
albumin), and transferred to a quartz spectrophotometer 
cuvette. A volume of 0.38 mL of buffer B (25% w/v 
saponin, 50 mmol/L KH2PO4, 5 mmol/L MgCl2, 5% 
w/v bovine serum albumin, 0.12 mmol/L cytochrome 
c-oxidized form, 0.2 mmol/L NaN3) was then added for 5 
min at room temperature. The reaction was started with 0.15 
mmol/L NADH and was monitored for 5 min, reading the 
absorbance at 550 nm using a Lambda 3 spectrophotometer 
(PerkinElmer, Waltham, MA). Results were expressed as 
nmol of cyt c reduced/min/ mg mitochondrial protein. The 
activities of Complexes I, II, III and IV were measured 
spectrophotometrically as reported by [55].
Mice
For orthotopic experiments, C57BL/6 mice (not 
carrying Kras and TP53 mutations and bred at the animal 
facility of the Molecular Biotechnology Center, University 
of Turin, Italy) were injected in the pancreas with 1x105 
K8484 cells in Matrigel (1:5; BD) and euthanized after 15 
or 30 days. Blood was collected by cardiac puncture using 
a 22-gauge needle and a 1 ml syringe from mice previously 
anesthetized. Acute pancreatitis was induced in C57BL/6 
mice by six hourly intraperitoneal (i.p.) injections of 50 μg/
kg of caerulein (kindly provided by Dr F. Bussolino, IRCCS 
Candiolo, Turin, Italy). Mice were sacrificed 7 hours after 
the first caerulein injection. Chronic pancreatitis was 
induced by six hourly i.p. injections of 50 μg/kg caerulein 
once a week for 4 weeks. Mice were sacrificed 3 days after 
the final caerulein injection. GEM mice carrying single-
mutated KrasG12D (KC) were bred and maintained under 
saprophytic and pathogen-free conditions at the animal 
facilities of the Molecular Biotechnology Center and 
treated in accordance with EU and institutional guidelines. 
Diabetes was induced by housing C57BL/6 mice with High-
Fat diet containing (w/w) 60% fat, 18% protein and 22% 
carbohydrate (Thermo Fisher D12492). In the sixth week 
mice were subjected to intravenous glucose tolerance tests 
as described below.
Intravenous glucose tolerance tests
The intravenous glucose tolerance tests were 
performed (n=5 per test group for each test) following 
six weeks of High-Fat diet. Animals were studied after an 
overnight fast and anesthetized, a bolus of glucose (1 g/kg) 
was injected i.v. and blood was sampled at 0, 1, 10, 30 and 
50 min for plasma glucose analyses with an Accu-CHEK 
Aviva device.
Immunohistochemical staining
Pancreatic tissues from WT and KC mice at 3 and 
9 months of age mice and tumors arose after orthotopic 
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injection of K8484 cells were formalin-fixed and paraffin-
embedded. Then tissues were cut into 3 μm thick slices 
and peroxidase activity was inhibited by immersing the 
slides in 3% hydrogen peroxide aqueous solution for 10 
minutes. Pancreatic tissue samples were pretreated by 
microwave antigen retrieval using citrate buffer (Dako, 
Milano, Italy) and incubated with CPSII antibody (1:300, 
30 minutes at room temperature, order number ab99312, 
Abcam, Cambridge, UK) or with pH9 buffer and stained 
with GDH1 (1:400, 30 minutes at room temperature, 
order number ab166618, Abcam). Than rabbit En Vision 
system (Dako) was used before diaminobenzidine 
tetrahydrochloride (Dako) incubation. Negative and positive 
controls were performed to set up the staining protocol. All 
slides were stained for the same antigen together with the 
same antigen retrieval buffer and antibody dilution. Tissues 
were examined in a double-blind fashion and digital images 
of representative area were taken.
Preparation of murine blood samples for MS 
analysis
Aliquots (200 μl) of murine whole blood were 
collected in tubes containing heparin. Samples were 
deproteinized with an equal amount (200 μl) of 2 mM 
N-Acetyl-L-Glutamine (Sigma Aldrich) dissolved in 1:9 
H2O-acetonitrile, vortexed, and kept on ice for 10 min. 
After centrifugation at 4000 rpm for 10 min at 4°C, 
supernatants were transferred into a clean tube. Samples 
were then stored at -20°C and glutamine analysis executed 
within two days.
Preparation of murine blood samples for HPLC 
analysis
Aliquots (100-200 μl) of whole blood from mice 
orthotopically injected with K8484 cells, as previously 
described, were collected in tubes containing K2-EDTA. 
After centrifugation at 3500 rpm for 5 min at 4° C, plasma 
was transferred into a clean tube and deproteinized with a 
5-sulfosalicylic solution (15%, w/v), vortexed for 30 sec 
and left at room temperature for 15 min. Samples were 
then stored at -80°C. Samples are diluted in 0.2M lithium 
citrate (pH 2.20) containing the internal standard N-valine. 
The amino acid analysis method was based on ion exchange 
chromatography with post column derivatization with 
Ninhydrin (Amino Acid Analyzer 30 Biochrom Ldt, UK) 
[15, 16].
Tissue sample and histopathology
Mice were euthanized at the indicated time points, 
necropsied and examined for the presence of tumor 
masses. Tumor masses were fixed in 4% (v/v) neutral-
buffered formalin (Sigma-Aldrich) overnight, transferred 
to 70% ethanol, and paraffin-embedded. For histological 
analysis, formalin-fixed paraffin-embedded tissue sections 
of 5μm were cut and stained with hematoxylin-eosin.
Statistical analysis
Statistical analyses were performed using the 
unpaired Student’s t test and two-way ANOVA with 
Sidak’s post hoc test, as appropriate (GraphPad Prism4 
software). For all experiments with error bars, SEM was 
calculated to indicate the variation within each experiment 
and data, and values represent mean ± SEM.
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SUPPLEMENTARY MATERIALS
Oligonucleotide primer sequences for SybrGreen qRT-PCR
Gene Sense Antisense
Human ASCT2 CCGCTTCTTCAACTCCTTCA GTAAACCCACATCCTCCATCTC
Mouse ASCT2 GGTTCTGCCTCTCATCTACTTC CCACACCATTCTTCTCCTCTAC
Human LAT1 GTGGCCTCTTGGCTATTTCT GTGTCTGCCTTTCTTGTCTCT
Mouse LAT1 GCTGTCGTTCAGTAGCATAGAG GGTGATGTGCAAGTCTCAGTAG
Human GLS AGGTGGTGATCAAAGGGTAAAG TCCATGTCCATAGCTGACAAAG
Mouse GLS CCATCAAGCCTCACATCTCTAC GTGCAGTTTCGCTGTCTTTAC
Human GDH1 CATGGCTGACTTCCTCACTATC GGGCTGACTTGGATTGACTT
Mouse GDH1 ATCGGGTGCATCTGAGAAAG CAGGTCCAATCCCAGGTTATAC
Human GDH2 GGAATGACACCAGGGTTTAGAG TCAGACTCACCAACAGCAATAC
Human AST CAACTGGGATTGACCCAACT GGAACAGAAACCGGTGCTT
Mouse AST GCGCCTCCATCAGTCTTTG ATTCATCTGTGCGGTACGCTC
Human GPAT GTCAGGAGAGTGCTGGTATTG CCCATTCCCTTGTGTGATTTG
Mouse GPAT AGTCGCTTCACCACCAATAA CAGTCCTTCCACTGACAGATAC
Human CPSII CTGAAGGGATGGAAGGAGATTG TACGTGACACAGTTGCCATAG
Mouse CPSII GCTGGCAGACAAGGTCTATTT ACCATCTGGGCGTTCATTAC
Human β-actin CGCCGCCAGCTCACCATG CACGATGGAGGGGAAGACGG
Mouse GAPDH CATGTTCCAGTATGACTCCACTC GGCCTCACCCCATTTGATGT
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Supplementary Table 1: Glutamine uptake in mouse and human cell lines
Cell lines Type K-Ras a TP53 b Δ 120-0%Unc P value d
HPDE Control Human Pancreatic 
Ductal Epithelial cells
Wt Wt 11,6 ± 2.6
MDA-MB-231
Human Breast 
Adenocarcinoma
Mut (p.G13D) Mut (p.R280K) 2.3 ± 1.52 n.s.
MCF7 Human Breast 
Adenocarcinoma
Wt Wt 15.4 + 0.12 n.s.
BT494
Human Breast 
Adenocarcinoma
Wt Mut (rear.) 7.0 + 0.08 n.s.
DU4475
Human Breast 
Adenocarcinoma
Wt Wt 77.3 + 0.43 ***
NCI-H441 Human NSCLS Mut (p.G12V) Mut (p.R158L) 23.7 ± 8.65 n.s.
BxPC3 Human PDAC Wt Mut (p.Y220C) 12 ± 3,61 n.s.
PT45 Human PDAC Mut (p.G12C) Mut (p.R280K) 35.6 ± 4.41 ***
MiaPaCa2 Human PDAC Mut (p.G12C) Mut (p.R248W) 20.8 ± 4.56 ***
Panc1 Human PDAC Mut (p.G12D) Mut (p.R273H) 25.7 ± 3.75 ***
T3M4 Human PDAC Mut (p.Q61H) Mut (p.Y220C) 60.0 ± 5.73 ***
Hs766T Human PDAC Mut (p.Q61H) Mut (rearr.) 56.0 ± 5.54 ***
CFPAC1 Human PDAC Mut (p.G12V) Mut (p.C242R) 62.0 ± 5.83 ***
Colo.357-L3.6pl Human PDAC Mut (p.G12D) Wt 57.3 ± 5.60 ***
K8484 Mouse PDAC Mut (p.G12D) Mut (p.R172H) 72.0 ± 6.28 ***
DT4313 Mouse PDAC Mut (p.G12D) Wt 32.0 ± 4.23 **
DT6606 Mouse PDAC Mut (p.G12D) Wt 52.0 ± 5.35 ***
a-b Molecular genotypes of analyzed human and murine cell lines. Mutational status was obtained from ATCC (www.atcc.
org) and from Cancer Cell Line Encyclopedia (CCLE).
c %Un delta between 120 min and 0 min ± SEM.
d *P <.05; ** P <.01;*** P <.001 significance values, compared to those obtained with the HPDE cell line.
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Supplemental Figure 1: PDAC cells rely on glutamine to support nucleotide biosynthesis. (A-F) mRNA expression analysis 
of: GLS (A), GDH1 (B), GDH2 (C), AST (F), GPAT (E) and CPSII (F) in normal pancreatic cells HPDE (white bar), human pancreatic 
tumor cells BxPC3, PT45, MiaPaCa2, PANC1, T3M4, Hs766T, CFPAC1, Colo-357-L3.6pl (light grey bars), murine pancreatic tumor cells 
K8484, DT6606, DT4313 (black bars) and non-PDAC cells NCI-H441 and MDA-MB-231 (dark grey bars). mRNA expression levels are 
represented as 2-DCt and results are expressed as mean±SEM of triplicates of two independent experiments. * P <.05; ** P <.01;*** P 
<.001 values different from those obtained with the HPDE cell line.
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Supplemental Figure 2: GDH1 and CPSII expression correlate with tumor progression. (A-H) IHC staining of pancreas 
sections of control WT mice (A-E), 3 months old (B-F) and 6 months old (C-G) KC mice and of C57BL/6 mice injected orthotopically with 
K8484 cells. (D-H) Tissues were stained with anti GDH1 (A-D) or anti CPSII (E-H) antibody and examined in a double-blind fashion and 
digital images of representative areas were taken.
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Supplemental Figure 3: In vivo glutamine measurement with MS. (A) C57BL/6 mice were injected orthotopically into the 
pancreas with K8484 cells. Pancreases were collected and weighed at 0, 15 and 30 days after cell injection. (B) Graph represents percentage 
of blood glutamine compared to time 0 in orthotopically injected C57BL/6 mice evaluated using a MS instrument at the indicated time 
points. Results are represented for each mouse (10-15 mice/time point) and mean±SEM is indicated. (C-D) Percentage of blood glutamine 
in KC mice (C) and WT mice (D) (3-10 mice/group) at indicated time points compared to control group (mice <2 months old) is plotted for 
each mouse. Mean±SEM is indicated. * P <.05; ** P <.01; *** P <.001 values showing a significant difference of days 15 and 30 compared 
to day 0 for the orthotopic model, and KC and WT mice older than 2 months compared to mice less than 2 months old.
